Burn Center Organization and Cellular Therapy Integration: Managing Risks and Costs
Michèle Chemali1,2, Alexis Laurent1, Corinne Scaletta1
1Department of Musculoskeletal Medicine, Plastic, Reconstructive and Hand Surgery Service, Lausanne University Hospital, University of Lausanne, Switzerland.
Summary
Severe burn care integrates multidisciplinary specialists and cell therapies for better patient outcomes. This study addresses optimizing resources and navigating regulatory challenges for advanced burn treatments.
Area of Science:
- Regenerative Medicine
- Burn Surgery
- Healthcare Management
Background:
- Severe burn victim management necessitates multidisciplinary collaboration for optimal healthcare.
- Cellular therapies are increasingly integrated into burn patient care, improving treatment efficiency and outcomes.
- Fluctuating patient admissions and evolving European regulations pose challenges to resource utilization and therapy translation.
Purpose of the Study:
- To outline key considerations for burn care, focusing on architectural and organizational aspects of burn centers.
- To address the management of cellular therapy products within clinical settings.
- To provide guidelines for navigating evolving, restrictive regulations concerning standardized cell therapies.
Main Methods:
- Review of integrated risk and cost management strategies based on clinical experience.
- Analysis of architectural and organizational factors in burn centers.
- Examination of cellular therapy product management protocols.
Main Results:
- Integration of cell therapies has led to reduced hospital stays, shorter mechanical ventilation, fewer complications, and decreased mortality.
- Optimized resource utilization is crucial due to fluctuating patient admission rates.
- Proactive management of risks and costs is essential for preserving clinical care and cellular therapies.
Conclusions:
- Effective burn care requires a holistic approach encompassing specialized facilities, efficient cellular therapy management, and adaptive regulatory navigation.
- Integrated risk and cost management strategies are vital for sustaining high-quality care and innovative therapies for severe burn patients.
- Addressing policy and organizational challenges is critical for the continued advancement and accessibility of cellular therapies in burn management.
More Related Videos
Related Concept Videos
Combination Therapies and Personalized Medicine
5.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K
Tumor Immunotherapy
804
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
804
Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
218
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
218
Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Cancer Therapies
8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)